Fused heterocyclic compound
US10017487B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2016 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Mar 25, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65517
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.